Is Gilead Sciences a Great Dividend Stock?
Here's an objective evaluation.
Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past.
This golden age is also presenting tremendous opportunities for investors. Biotech stocks offer the potential for huge long-term returns. Here’s what you need to know to invest in the best biotech stocks on the market.
The biotech industry is rapidly changing in the current economic climate. Find the latest information in the newsfeed at the end of this article.
The best biotech stocks to buy right now boast strong pipelines, and some already have winning drugs on the market. The COVID-19 pandemic has also created some tremendous opportunities for biotechs developing potential treatments and vaccines. Here are a few companies that investors should watch closely.
|Axsome Therapeutics (NASDAQ:AXSM)||Neuroscience|
|bluebird bio (NASDAQ:BLUE)||Cancer, rare diseases|
|Novavax (NASDAQ:NVAX)||Infectious diseases|
|Vertex Pharmaceuticals (NASDAQ:VRTX)||Rare diseases|
Source: The Motley Fool
Axsome (NASDAQ:AXSM) has a lead candidate, AXS-05, that is being evaluated in three phase 3 studies targeting depression and Alzheimer’s disease agitation as well as in a phase 2 study for smoking cessation. The biotech also is testing experimental migraine drug AXS-07 in a phase 3 study and has two other drug candidates in earlier-stage clinical trials.
If approved, AXS-05 could generate peak annual sales of at least $1 billion, making it a blockbuster drug, with one analyst projecting peak sales of $2.6 billion. Analysts haven’t weighed in on how much revenue AXS-07 or any of Axsome’s other candidates might make. But the potential for AXS-05 alone makes Axsome an attractive small-cap biotech stock to buy right now.
Bluebird bio (NASDAQ:BLUE) already has one drug approved in Europe for treating the rare blood disorder transfusion-dependent beta-thalassemia -- Zynteglo. The drug is in a phase 3 study in the U.S. Bluebird is also evaluating Lenti-D in phase 3 studies for treating a rare genetic disease called cerebral adrenoleukodystrophy.
In addition to these fully owned programs, Bluebird and Bristol Myers Squibb (NYSE:BMY) filed for U.S. and European regulatory approvals for ide-cel in treating multiple myeloma, a type of blood cancer. Bluebird’s pipeline also includes candidates in phase 1 studies targeting other genetic diseases and types of cancer.
Zynteglo could reach blockbuster status, generating peak annual sales of close to $1.9 billion. Some analysts think that Lenti-D could rake in up to $4 billion per year if approved in the U.S. and Europe. Bluebird will receive royalties from BMS’ sales of ide-cel (assuming it wins approval) that could also be substantial: Analysts project sales for the drug could top $2 billion annually. All of this adds up to a big growth runway for Bluebird over the next few years.
Novavax (NASDAQ:NVAX) made a huge comeback in 2020 after the stock lost nearly 90% of its value in 2019 following a second late-stage flop for respiratory syncytial virus vaccine candidate ResVax. The small biotech’s rise from the ashes stemmed from two important developments.
The company reported overwhelmingly positive results from a late-stage study of experimental flu vaccine NanoFlu. The company now plans to pursue Food and Drug Administration approval of the vaccine. Analysts project that, if approved, NanoFlu could generate peak annual sales of as much as $1.7 billion.
Novavax could have an even bigger winner with its COVID-19 vaccine candidate NVX-CoV2373. It’s one of the leading vaccine candidates that use a protein subunit (a single protein molecule) to spur an immune response against the novel coronavirus. The biotech announced positive results from a phase 1 study of the experimental vaccine in August, prompting some analysts to declare NVX-CoV2373 as potentially the best-in-class among coronavirus vaccine candidates in development.
The U.S. government signed a $1.6 billion agreement with Novavax to fund the late-stage development and manufacturing of its COVID-19 vaccine, including supplying 100 million doses if it’s successful in clinical testing. Novavax has also inked supply deals in the United Kingdom and India.
Vertex (NASDAQ:VRTX) enjoys a virtual monopoly in treating the underlying cause of cystic fibrosis (CF), a rare genetic disease that results in the excessive buildup of mucus in the lungs and digestive system. Its newest CF drug, Trikafta/Kaftrio, could expand the addressable patient population by more than 50% by targeting a genetic mutation estimated to occur in 90% of CF patients.
The company’s pipeline includes other promising CF drugs in phase 2 testing. Vertex is also seeking to expand beyond CF, with phase 2 programs targeting pain and the rare genetic disease alpha-1 antitrypsin deficiency, which can cause symptoms including shortness of breath, lung infections, and fatigue.
In addition, Vertex’s early-stage programs could be game changers. It’s partnering with CRISPR Therapeutics (NASDAQ:CRSP) to test gene-editing therapies (treatments that involve changing DNA sequences) targeting rare blood diseases beta-thalassemia and sickle cell disease. The group hopes to soon advance to phase 1 testing an experimental drug that holds the potential to cure type 1 diabetes, a disease that affects over 1.1 million people worldwide. Although analysts haven’t projected peak sales for these pipeline candidates, Vertex could be sitting on a gold mine if all goes well.
What exactly is a biotech? It’s a company that uses living organisms (for example, bacteria or enzymes) to make drugs. This use of living organisms differentiates biotechs from pharmaceutical companies, which use chemicals to develop drugs.
There are four major steps for biotechs in developing new drugs:
Clinical testing typically involves three phases:
A drug candidate must successfully make it through each phase to advance to the next. Once a drug successfully completes a phase 3 trial by demonstrating safety and efficacy in treating the target condition, the biotech will file for regulatory approval using the clinical data from the study. In the U.S., the FDA oversees approvals for new drugs.
Investors should pay close attention to which phases a company’s drug candidates are in. The later the phase, the less risk there usually is. It’s also important to consider a drug candidate’s peak annual sales -- the highest level of sales per year that analysts project. The higher the better.
In addition, a biotech with more experimental drugs in its pipeline (the term used to refer to all a company’s drugs that are in development) will tend to have less risk than a biotech with only one or a very few drug candidates.
Another important thing to watch with biotechs is their financial positions. Most biotechs don’t achieve profitability until they successfully launch one or more drugs in the market. They require significant amounts of cash to fund operations and advance their pipeline candidates. Companies often issue new shares to raise the cash needed, which lowers the value of existing shares. Some biotechs also receive money through partnerships with larger drugmakers and grants from government agencies and nonprofit organizations.
It’s possible that these biotechs’ clinical studies could flop. Even if testing goes well, there’s no guarantee that the companies will win regulatory approvals for their drugs. Those are two of the main risks associated with investing in biotech stocks. Companies can also run out of money to fund clinical studies, complete regulatory filings, and/or bring new drugs to market.
But Axsome, Bluebird, Novavax, and Vertex could also be successful with their clinical studies and win approvals to launch their promising drugs. It’s also possible that any of these companies could be acquired by a larger drugmaker. The chances appear to be good that these stocks will generate tremendous long-term gains for patient investors.
Here's an objective evaluation.
Rivals and vaccine developers have pushed this early leader out of the spotlight.
Daniel O'Day has made increasingly larger deals in an effort to improve the company's portfolio of cancer drugs.
The stock has a high yield -- and it also has something even more important.
Big shot organizations are recommending against the use of Gilead's antiviral to treat COVID-19.
These stocks boast dividend yields that outperform many on the S&P 500.
They're especially valuable for retirees and investors who are concerned about recession or volatility.
Here are three reasons why the answer is "yes."
The FDA has granted emergency use authorization to the first COVID-19 treatment option that uses a pair of antibodies to neutralize the novel coronavirus.
The company's HIV franchise faces threats from many different directions.